Three new HIV vaccine concepts which rely on high-tech designer proteins are being trialled to see if they can stop the virus.
L’expertise universitaire, l’exigence journalistique
Articles sur HVTN 702
Ensemble des articles
For the next five years South Africa will be leading one of the latest large-scale trials for a vaccine for HIV.
Two major clinical trials will be conducted in South Africa in 2016 to test ways of preventing new HIV infections.
Les contributeurs les plus fréquents
-
Medical Scientist at the National Institute for Communicable Diseases; Research Associate at CAPRISA; Research Professor in the School of Pathology, University of the Witwatersrand
-
Research Professor and DST/NRF SARChI Chair of Virus-Host Dynamics, National Institute for Communicable Diseases, CAPRISA Research Associate, University of the Witwatersrand
-
Medical Scientist, National Institute for Communicable Diseases
-
Medical Scientist, National Institute for Communicable Diseases
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
